

COVID-19 immunization threshold(s): an analysis

Luis Alfredo Bautista Balbás¹, Mario Gil Conesa², Blanca Bautista Balbás³, Ainhoa Alcaide Jiménez², Gil Rodríguez Caravaca².

1 Hospital Virgen de la Poveda, Villa del Prado, Madrid, Spain.

2 Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain.

3 Hospital Son Llatzer, Palma de Mallorca, Spain

1 Table of Contents

| | |
|-------------------------------|----|
| 2 Abstract..... | 2 |
| 3 Introduction | 3 |
| 4 Materials and methods | 3 |
| 5 Results..... | 5 |
| 6 Discussion | 8 |
| 7 Bibliography..... | 10 |

2 Abstract

As COVID-19 vaccine research efforts seem to be yielding the first tangible results, the proportion of individuals needed to reap the benefits of herd immunity is a key element from a Public Health programs perspective.

This magnitude, termed the critical immunization threshold (q), can be obtained from the classical SIR model equilibrium equation, equaling $(1 - 1/R_0)/\epsilon$, where R_0 is the basic reproduction number and ϵ is the vaccine efficacy. When a significant proportion of the population is already immune, this becomes $(n - 1/R_0)/\epsilon$, where n is the proportion of non-immune individuals. A similar equation can be obtained for short-term immunization thresholds(q_t), which are dependent on R_t .

qs for most countries are between 60-75% of the population. Current q_t for most countries are between 20-40%.

Therefore, the combination of gradual vaccination and other non-pharmaceutical interventions will mark the transition to the herd immunity, providing that the later turns out to be a feasible objective. Nevertheless, immunization through vaccination is a complex issue and many challenges might appear.

Keywords: COVID-19, COVID-19 Vaccines, basic reproduction number, effective reproduction number, herd immunity, non-pharmaceutical interventions.

3 Introduction

Herd immunity is a phenomenon observed when a sufficiently large percentage of a population is immune to an infectious disease, hence reducing the risk of infection of the non-immune individuals. This is related to the fact that a significant proportion of contacts of an infectee will not be susceptible to the disease. When this phenomenon is present, contagions or limited outbreaks or might still take place but large-scale sustained or exponential transmission will not occur.

Herd immunity cutoff (H) is classically calculated by $H = 1 - (1/R_0)$ ¹ where R_0 is the basic reproduction number, the number of infections each infected case is expected to cause when all the population is susceptible and no special measures are implemented. If the vaccine provides partial protection, $H = \frac{1-(1/R_0)}{\epsilon}$ where ϵ is the proportional vaccine efficacy. The R_0 of infectious diseases can vary widely between populations due to cultural behaviors, population density and other factors, so local estimates should be used if available; for example in measles it varies between 12-18.²

In the context of the COVID-19 ongoing pandemic, herd immunity was proposed as a possible protection mechanism. However, relying on herd immunity has a number of issues due to the lacking evidence about long-term protection³. As the results of phase II/III trials of COVID-19 vaccines are made available⁴, the discussion now pertains to the challenges of achieving herd-immunity through vaccination⁵.

In the SIR compartmental models of epidemic diseases, individuals are classified in three compartments: susceptible, infected and recovered; S , I and R are their respective proportions, ($S + I + R = 1$). As the epidemic unfolds the number of individuals in the S compartment decreases, since these individuals are moved to other compartments. We assume there is not any shift from the R compartment to the S compartment (immunity loss), as this would add a currently unknown rate to the model. In any case, the reproduction number over time can be calculated by $R_t = R_0 S_t$ where S_t is the proportion of susceptible individuals at time t . If compartmental models are specified with immunity loss (SEIRS model), some periodic oscillations are observed until equilibrium is reached⁶.

This article includes a small theoretical analysis regarding short and long term herd immunity in relation to reproduction numbers, in partially immune populations, and the derived interpretations in the context of COVID-19.

4 Materials and methods

The herd immunity cutoff can be obtained via the SIR equilibrium, which is reached when $R_0 S_e = 1$ (where S_e is the proportion of susceptible individuals at the equilibrium). For a partially-immune population in which vaccination will be introduced, assuming both vaccination and positive antibodies provide lifelong immunity, S_e can be expressed as $S_e = 1 - q\epsilon - g$ where q is the *critical immunization threshold* (the proportion of the population that should be vaccinated to reach the equilibrium, where herd immunity starts to act), g is the seroprevalence (proportion of

already immune individuals) before vaccination and n the proportion of non-immune individuals, so that $1 = g + n$. From this, the q would be:

$$q = (n - 1/R_0)/\epsilon$$

Effective short-term herd immunity can also be obtained as a function of current estimated effective reproductive numbers ($R(t)$) at time t in time-since-infection models, which can be calculated by the methods discussed by other authors^{7,8,9}. The instantaneous reproduction number (R_t^i) is the number of individuals each individual infected at time t is expected to infect, should conditions remain the same. It can be decomposed in: $R_t^i = S_t C_t p_t$, where C_t is the contact rate of infected individuals at time t (thus influenced by events restrictions, social distancing, etc.), and p_t is the infection probability of their contacts (thus influenced by wearing masks, increasing ventilation, etc). R_t^i , C_t and p_t would be applicable to the individuals that got infected at t if conditions remained the same⁷, and more precisely, C_t and p_t would be the average C and p of the infected population at t , both weighted by individual infectivities⁹ at that time point. The case reproduction number R_t^c is the number of individuals each infected individual at time t actually infects, so it would be $R_t^c = \sum_{s=t}^M S_t C_t^c p_t^c$, with time-dependent S proportion, actual cases contact rates C_t^c and actual case infection probabilities p_t^c at each time between t and M , M being the number of periods in which an individual is infective. (In more elaborate analysis N transmission routes could be used (with their N respective contact rates and N infection probabilities), so that $C_t * p_t$ would be a case of matrix multiplication delivering the number of infective contacts).

Let the vaccination be considered at time t , with a partially immune population. Equilibrium would be reached when $R_t^i = 1 = (n_t - q_t \epsilon) C_t p_t$, where n_t is the proportion of non-immune individuals at t and q_t the proportion of the population that should be vaccinated to reach the equilibrium, should future C_s and p_s remain the same. $C_t p_t$ can be calculated for any previous time period (u period(s) before t), and used assuming circumstances will be similar, based on knowledge of cultural habits, contact rates and interactions: $C_t p_t \approx C_{t-u} I_{t-u} = \frac{R_{t-u}^e}{S_{t-u}}$. From this:

$$q_t = \frac{n_t - [1/(C_t p_t)]}{\epsilon} \approx \frac{n_t - [1/(R_{t-u}^e / S_{t-u})]}{\epsilon}$$

The same can be applied to the R_0 from the SIR model: $R_0 = C_0 p_0$ where C_0 is the average number of contacts during the the infectious period and p_0 the infection/contact probability. $C_t p_t$ can be understood as the R_0 we would estimate via a SIR model from a fully susceptible population with contact rates, infectiousness profiles, habits, etc. being the same as in t : In this case, $R_0 = C_0 p_0 \approx 1 C_t p_t$. The relationship between q and R_0 is also similar to that between q_t and R_t^i , probably because the underlying mechanism is the same.

We have obtained graphics displaying the relationship between R_0 and q , R_t and q_t , and $C_t R_t$ and R_t^i by using several common ϵ and S values, and calculated the q estimates for several countries/situations. Seroprevalence has been assumed by dividing total reported cases (from the COVID-19 CSSE-JHU dataset¹⁰) by total population (from WHO world population prospects¹¹). As R_0 estimates, we used the median (3.32) from the meta-analysis by Alimohamadi et al¹² and country estimates from Hilton et al¹³.

5 Results

The q of a population in which 90% individuals are susceptible and the vaccine has 95% efficacy, would be 68.3% if $R_0 = 3.32$ and 57.9 if $R_0 = 2.5$. Figure 1 displays the q curves as a function of R_0 , ϵ and g .




Figure 1: Critical Immunization Thresholds calculated for several situations. Continuous line: 100% vaccine efficacy (ϵ); dashed line: 90% vaccine efficacy, dotted line: 80% vaccine efficacy. Black: 0%

population is already immune (g); red: 10% population is immune; blue: 20% population is immune. Vertical green: $R_0=3.32$

The q_t of a population in which $S = 95\%$ and $\epsilon = 0.95$, would be 12.3% if $R_t = 1.2$ and 29.8 if $R_t = 1.5$. Figure 2 displays the q_t curves as a function of R_{t-1} , ϵ and g_{t-1} . Figure 3, shows R_t as a function of S_t and $C_t P_t$.




Figure 2: Short-term Critical Immunization Thresholds. Continuous line: 100% vaccine efficacy (ϵ); dashed line: 90% vaccine efficacy, dotted line: 80% vaccine efficacy. Black: 0% population is already immune (g); red: 10% population is immune; blue: 20% population is immune.

Table 1 displays the q calculated for several large countries.

Table 1: qs for several countries, calculated with per-country R_0 (from Hilton et al) or with a global estimate (3.32, from Alimohamadi et al). Number of reported cases as of 01-Jan-2021 is taken as the proportion of immune individuals.

| Country | R_0 | Immune proportion | q |
|--------------------------|-------|-------------------|-------|
| United States of America | 2.22 | 6.1 | 48.85 |
| United States of America | 3.32 | 6.1 | 63.78 |
| India | 2.78 | 0.7 | 63.33 |
| India | 3.32 | 0.7 | 69.18 |
| Brazil | 2.79 | 3.6 | 60.56 |
| Brazil | 3.32 | 3.6 | 66.28 |
| Russian Federation | 2.18 | 2.2 | 51.93 |
| Russian Federation | 3.32 | 2.2 | 67.68 |
| Mexico | 2.65 | 1.1 | 61.16 |
| Mexico | 3.32 | 1.1 | 68.78 |
| Sweden | 2.14 | 4.3 | 48.97 |
| Sweden | 3.32 | 4.3 | 65.58 |
| United Kingdom | 1.67 | 3.7 | 36.42 |
| United Kingdom | 3.32 | 3.7 | 66.18 |
| Spain | 2.00 | 4.1 | 45.90 |
| Spain | 3.32 | 4.1 | 65.78 |
| France | 2.01 | 4.0 | 46.25 |
| France | 3.32 | 4.0 | 65.88 |
| Ukraine | 2.15 | 2.5 | 50.99 |
| Ukraine | 3.32 | 2.5 | 67.38 |




Figure 3: R_t as a function of $C_t P_t$ (reflecting contacts, habits and preventive measures) and susceptible population (S_t). Dotted line: $C_t P_t = 0.8$; dotdash: $C_t P_t = 1$; dashed: $C_t P_t = 1.2$; two dashes: $C_t P_t = 1.5$; long dashes: $C_t P_t = 2$; continuous line: $C_t P_t = 3$. Vertical lines: 5% seroprevalence, 60% seroprevalence. As the proportion of susceptible population increases, preventive measures can be relaxed while maintaining epidemic control. If transgressions (sudden increases in $C_t P_t$) take place, if a population immunity is small the outbreak will probably be stronger.

6 Discussion

The critical immunization threshold depends on R number, percentage of susceptibles and vaccine efficacy. Many estimates are available for COVID-19 R_0 ; each model having its own

assumptions. These were obtained from early pandemic periods with partial implementation of protective measures, therefore maybe underestimating R_0 .

The proportion of immune individuals varies between countries. We used the number of reported cases, a conservative approach, given the under-reporting of cases. Reported cases range between 0-5% population in most countries. The initial seroprevalence study in Spain (April-May 2020) show similar ranges (5%)¹⁴. In 3609 adult volunteers from Liguria and Lombardia, a rate of 11% (95%CI: 10.0-12.1%) was observed¹⁵. In Kenyan blood-donors, up to 8% seroprevalence was observed in some urban counties¹⁶.

Actual future vaccine efficacy can only be subject to conjecture at present. The BNT162b2 mRNA Covid-19 Vaccine (by Pfizer®) has shown a 95% (95%CI: 90.3-97.6) protection against COVID-19 infection⁴. With the ChAdOx1 nCoV-19 vaccine (AZD1222), efficacy was 62.1 (95%CI 41.0-75.7) for the two-standard-doses regime, and 90.0% (67.4-97.0) for those who initially received a low dose instead¹⁷.

By using this data, COVID-19 q would be 60-70%. If we calculate q_t estimates for R_t s under 1.5, which is the case for developed and developing countries after the first wave of the pandemic;¹⁸ these would lie around 20-40%.

An important consequence of these graphs is that, at equilibrium, initially small variations of R are compensated by large proportions of vaccinated individuals, suggesting the benefits of vaccines might not be apparent at the initial periods.

This calculation has several limitations. We have used epidemiological models that do not take into account population heterogeneity and the non-random habits of particular mixing groups, an important limitation of herd immunity estimations¹⁹. As vaccination and contacts will not be random, this discussion is an approximation. Additionally, R_0 is always an estimate, and considerable differences can be observed between studies, rendering q calculation uncertain. Population growth, migrations and deceases have not been included. (If pre-pandemic population is used, newborns are susceptible, and infected-and-deceased should be excluded from the immunes).

Finally, vaccination and immunity is a complex process: Virus mutations and strains, vaccine hesitancy, efficacy in high-risk groups, protection duration, mucosal immunity, etc.⁵ Evidence is scarce regarding the duration of COVID-19 immunity³, and different kinds of immunity against other coronavirus might wane over years²⁰. Several rare cases of reinfections have been reported²¹, but still orders of magnitude smaller than the number of new infections; and booster vaccine doses might be required.

As advantages, this study can help better understand the road lying ahead. In the short term, the R_t will be kept lower than 2 in many areas due to contact restrictions, remote working, etc. Despite the public and private efforts, there is uncertainty regarding the number of vaccine courses available by the end of 2021 for many countries²²; in this context effective epidemic control can be achieved through a combination of preventive measures and gradual population vaccination²³. On the other hand, vaccine hesitancy has been observed in different countries (USA²⁴, Turkey²⁵,...), with undecided (~30%) or refusing individuals (~10%), and concern exists regarding their management. These percentages are not contradictory with reaching high

percentages of immunity, and gradual vaccination campaigns can allow these individuals to make an informed decision. It should be noted vaccination strategies include different objectives: maintaining essential services (targeting healthcare, police and other workers), reducing severe cases (targeting comorbidities or the elderly), or stopping the virus transmission (targeting other individuals)²⁶. As a lesser-priority group, asymptomatic COVID-19 cases with weaker immune response might benefit from receiving a booster dose²⁷.

Even if the q is not reached, reducing the susceptible population has advantages regarding smoother and less sudden epidemic outbreaks. Nevertheless, achieving q value through vaccination doesn't guarantee any lack of new contagions: if coverage varies between groups in a population, those with insufficient immunization can exhibit sustained transmission¹.

To conclude, we have illustrated the effect of population immunity in epidemic control is quantitative, and interdependent with contact rates and their determinants.

7 Bibliography

1. Fine P, Eames K, Heymann DL. "Herd immunity": A rough guide. [Article]. *Clinical Infectious Diseases*. 2011;52:911–916. Available from: <https://doi.org/10.1093/cid/cir007>
2. Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (r_0) of measles: A systematic review. [Article]. *The Lancet Infectious Diseases*. 2017;17:e420–e428. Available from: [https://doi.org/10.1016/s1473-3099\(17\)30307-9](https://doi.org/10.1016/s1473-3099(17)30307-9)
3. Randolph HE, Barreiro LB. Herd immunity: Understanding COVID-19. [Article]. *Immunity*. 2020;52:737–741. Available from: <https://doi.org/10.1016/j.immuni.2020.04.012>
4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. [Article]. *New England Journal of Medicine*. 2020; Available from: <https://doi.org/10.1056/nejmoa2034577>
5. Anderson RM, Vegvari C, Truscott J, et al. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. [Article]. *The Lancet*. 2020;396:1614–1616. Available from: [https://doi.org/10.1016/s0140-6736\(20\)32318-7](https://doi.org/10.1016/s0140-6736(20)32318-7)
6. Bjørnstad ON, Shea K, Krzywinski M, et al. The SEIRS model for infectious disease dynamics. [Article]. *Nature Methods*. 2020;17:557–558. Available from: <https://doi.org/10.1038/s41592-020-0856-2>
7. Cori A, Ferguson NM, Fraser C, et al. A new framework and software to estimate time-varying reproduction numbers during epidemics. [Article]. *American Journal of Epidemiology*. 2013;178:1505–1512. Available from: <https://doi.org/10.1093/aje/kwt133>
8. Wallinga J. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. [Article]. *American Journal of Epidemiology*. 2004;160:509–516. Available from: <https://doi.org/10.1093/aje/kwh255>
9. Fraser C. Estimating individual and household reproduction numbers in an emerging epidemic. [Article]. *PLoS ONE*. 2007;2:e758. Available from: <https://doi.org/10.1371/journal.pone.0000758>

10. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. COVID-19 data repository [Internet]. 2020 [cited 2020 Oct 28];Available from: <https://github.com/CSSEGISandData/COVID-19>
11. United Nations, Department of Economic and Social Affairs, Population Division (2019). World population prospects 2019, online edition. Rev. 1 [Internet]. 2020 [cited 2020 Dec 13];Available from: <https://population.un.org/wpp/Download/Standard/Population/>
12. Alimohamadi Y, Taghdir M, Sepandi M. Estimate of the basic reproduction number for COVID-19: A systematic review and meta-analysis. [Article]. *Journal of Preventive Medicine and Public Health*. 2020;53:151–157. Available from: <https://doi.org/10.3961/jpmph.20.076>
13. Hilton J, Keeling MJ. Estimation of country-level basic reproductive ratios for novel coronavirus (SARS-CoV-2/COVID-19) using synthetic contact matrices. [Article]. *PLOS Computational Biology*. 2020;16:e1008031. Available from: <https://doi.org/10.1371/journal.pcbi.1008031>
14. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in spain (ENE-COVID): A nationwide, population-based seroepidemiological study. [Article]. *The Lancet*. 2020;396:535–544. Available from: [https://doi.org/10.1016/s0140-6736\(20\)31483-5](https://doi.org/10.1016/s0140-6736(20)31483-5)
15. Vena A, Berruti M, Adessi A, et al. Prevalence of antibodies to SARS-CoV-2 in italian adults and associated risk factors. [Article]. *Journal of Clinical Medicine*. 2020;9:2780. Available from: <https://doi.org/10.3390/jcm9092780>
16. Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of antiSARS-CoV-2 IgG antibodies in kenyan blood donors. [Article]. *Science*. 2020;eabe1916. Available from: <https://doi.org/10.1126/science.abe1916>
17. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in brazil, south africa, and the UK. [Article]. *The Lancet*. 2020;Available from: [https://doi.org/10.1016/s0140-6736\(20\)32661-1](https://doi.org/10.1016/s0140-6736(20)32661-1)
18. Balbás LAB, Conesa MG, Caravaca GR, et al. COVID-19 effective reproductive ratio determination: An application, and analysis of issues and influential factors. [Article]. 2020;Available from: <https://doi.org/10.1101/2020.07.15.20154039>
19. Fox JP, Elveback L, Scott W, et al. Herd immunity: Basic concept and relevance to public health immunization practices. [Article]. *American Journal of Epidemiology*. 1971;94:179–189. Available from: <https://doi.org/10.1093/oxfordjournals.aje.a121310>
20. Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. [Article]. *Immunity*. 2020;53:248–263. Available from: <https://doi.org/10.1016/j.immuni.2020.07.005>
21. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: A case study. [Article]. *The Lancet Infectious Diseases*. 2020;Available from: [https://doi.org/10.1016/s1473-3099\(20\)30764-7](https://doi.org/10.1016/s1473-3099(20)30764-7)

22. So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: Cross sectional analysis. [Article]. *BMJ*. 2020;m4750. Available from: <https://doi.org/10.1136/bmj.m4750>
23. Fontanet A, Cauchemez S. COVID-19 herd immunity: Where are we? [Article]. *Nature Reviews Immunology*. 2020;20:583–584. Available from: <https://doi.org/10.1038/s41577-020-00451-5>
24. Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes toward a potential SARS-CoV-2 vaccine. [Article]. *Annals of Internal Medicine*. 2020;173:964–973. Available from: <https://doi.org/10.7326/m20-3569>
25. Akarsu B, Özdemir DC, Baser DA, et al. While studies on covid-19 vaccine is ongoing; the public's thoughts and attitudes to the future covid-19 vaccine. [Article]. *International Journal of Clinical Practice*. 2020;Available from: <https://doi.org/10.1111/ijcp.13891>
26. Wang W, Wu Q, Yang J, et al. Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study. [Article]. *BMJ*. 2020;m4704. Available from: <https://doi.org/10.1136/bmj.m4704>
27. Jeyanathan M, Afkhami S, Smail F, et al. Immunological considerations for COVID-19 vaccine strategies. [Article]. *Nature Reviews Immunology*. 2020;20:615–632. Available from: <https://doi.org/10.1038/s41577-020-00434-6>